Wei-Li’s research focuses on the molecular mechanism of skin diseases with the aim of developing more specific treatments for these devastating skin conditions. She has been developing gene therapy strategies for rare genetic skin disorders by grafting gene corrected skin sheet and cells on patients. She used her expertise to develop pre-clinical models to test these strategies and this has led to phase I gene therapy trials for Netherton syndrome and dystrophic epidermolysis bullosa in which she was a non-clinical lead. She also has interest in the common skin disease eczema and has been developing a small molecule therapy for this condition.